24 results on '"DePalma, S"'
Search Results
2. HTA41 Surrogate Endpoints in Oncology: A Review of Recent Health Technology Appraisals in the United Kingdom
- Author
-
Wissinger, E., Koufopoulou, M., Fusco, N., Stewart, F., Oladapo, T., Depalma, S., Devani, D., and Rangi, N.D.
- Published
- 2023
- Full Text
- View/download PDF
3. HTA24 The Use of Real-World Data in Decision Making for Oncology: A Review of Recent Health Technology Appraisals in the United Kingdom
- Author
-
Koufopoulou, M., Wissinger, E., Oladapo, T., Stewart, F., Depalma, S., Devani, D., Rangi, N.D., and Fusco, N.
- Published
- 2023
- Full Text
- View/download PDF
4. ORE identifies extreme expression effects enriched for rare variants
- Author
-
Richter, F, primary, Hoffman, G E, additional, Manheimer, K B, additional, Patel, N, additional, Sharp, A J, additional, McKean, D, additional, Morton, S U, additional, DePalma, S, additional, Gorham, J, additional, Kitaygorodksy, A, additional, Porter, G A, additional, Giardini, A, additional, Shen, Y, additional, Chung, W K, additional, Seidman, J G, additional, Seidman, C E, additional, Schadt, E E, additional, and Gelb, B D, additional
- Published
- 2019
- Full Text
- View/download PDF
5. Familial Dilated Cardiomyopathy Caused by an Alpha-Tropomyosin Mutation: The Distinctive Natural History of Sarcomeric DCM
- Author
-
Lakdawala, NK, Dellefave, L, Sparks, E, Cirino, A, Depalma, S, Funke, B, Colan, SD, Watkins, H, Robinson, P, Redwood, CS, Seidman, CE, Seidman, JG, McNally, EM, and Ho, CY
- Published
- 2016
6. PO-0945: Modeling and simulation of simultaneous using of two superficial hyperthermia antennas
- Author
-
Di Dia, A., primary, Depalma, S., additional, Bresciani, S., additional, Maggio, A., additional, Miranti, A., additional, Poli, M., additional, Gabriele, P., additional, Garibaldi, E., additional, and Stasi, M., additional
- Published
- 2016
- Full Text
- View/download PDF
7. Simultaneous using of two superficial hyperthermia antennas
- Author
-
Di Dia, A., primary, Depalma, S., additional, Bresciani, S., additional, Maggio, A., additional, Miranti, A., additional, Poli, M., additional, Garibaldi, E., additional, Gabriele, P., additional, and Stasi, M., additional
- Published
- 2016
- Full Text
- View/download PDF
8. 16S ribosomal RNA sequence analysis for determination of phylogenetic relationship among methylotrophs
- Author
-
Tsuji, K., primary, Tsien, H. C., additional, Hanson, R. S., additional, DePalma, S. R., additional, Scholtz, R., additional, and LaRoche, S., additional
- Published
- 1990
- Full Text
- View/download PDF
9. Familial Dilated Cardiomyopathy Caused by an Alpha-Tropomyosin Mutation The Distinctive Natural History of Sarcomeric Dilated Cardiomyopathy
- Author
-
Lakdawala, NK, Dellefave, L, Redwood, CS, Sparks, E, Cirino, AL, Depalma, S, Colan, SD, Funke, B, Zimmerman, RS, Robinson, P, Watkins, H, Seidman, CE, Seidman, JG, McNally, EM, and Ho, CY
- Subjects
heart failure ,genetics ,cardiomyopathy - Abstract
OBJECTIVES: We sought to further define the role of sarcomere mutations in dilated cardiomyopathy (DCM) and associated clinical phenotypes. BACKGROUND: Mutations in several contractile proteins contribute to DCM, but definitive evidence for the roles of most sarcomere genes remains limited by the lack of robust genetic support. METHODS: Direct sequencing of 6 sarcomere genes was performed on 334 probands with DCM. A novel D230N missense mutation in the gene encoding alpha-tropomyosin (TPM1) was identified. Functional assessment was performed by the use of an in vitro reconstituted sarcomere complex to evaluate ATPase regulation and Ca(2+) affinity as correlates of contractility. RESULTS: TPM1 D230N segregated with DCM in 2 large unrelated families. This mutation altered an evolutionarily conserved residue and was absent in >1,000 control chromosomes. In vitro studies demonstrated major inhibitory effects on sarcomere function with reduced Ca(2+) sensitivity, maximum activation, and Ca(2+) affinity compared with wild-type TPM1. Clinical manifestations ranged from decompensated heart failure or sudden death in those presenting early in life to asymptomatic left ventricular dysfunction in those diagnosed during adulthood. Notably, several affected infants had remarkable improvement. CONCLUSIONS: Genetic segregation in 2 unrelated families and functional analyses conclusively establish a pathogenic role for TPM1 mutations in DCM. In vitro results demonstrate contrasting effects of DCM and hypertrophic cardiomyopathy mutations in TPM1, suggesting that specific functional consequences shape cardiac remodeling. Along with previous reports, our data support a distinctive, age-dependent phenotype with sarcomere-associated DCM where presentation early in life is associated with severe, sometimes lethal, disease. These observations have implications for the management of familial DCM.
- Full Text
- View/download PDF
10. F.458 - Simultaneous using of two superficial hyperthermia antennas.
- Author
-
Di Dia, A., Depalma, S., Bresciani, S., Maggio, A., Miranti, A., Poli, M., Garibaldi, E., Gabriele, P., and Stasi, M.
- Published
- 2016
- Full Text
- View/download PDF
11. Neither cardiac mitochondrial DNA variation nor copy number contribute to congenital heart disease risk.
- Author
-
Willcox JAL, Geiger JT, Morton SU, McKean D, Quiat D, Gorham JM, Tai AC, DePalma S, Bernstein D, Brueckner M, Chung WK, Giardini A, Goldmuntz E, Kaltman JR, Kim R, Newburger JW, Shen Y, Srivastava D, Tristani-Firouzi M, Gelb B, Porter GA Jr, Seidman JG, and Seidman CE
- Subjects
- DNA Copy Number Variations genetics, Humans, Mitochondria genetics, Mutation genetics, DNA, Mitochondrial genetics, Heart Defects, Congenital genetics
- Abstract
The well-established manifestation of mitochondrial mutations in functional cardiac disease (e.g., mitochondrial cardiomyopathy) prompted the hypothesis that mitochondrial DNA (mtDNA) sequence and/or copy number (mtDNAcn) variation contribute to cardiac defects in congenital heart disease (CHD). MtDNAcns were calculated and rare, non-synonymous mtDNA mutations were identified in 1,837 CHD-affected proband-parent trios, 116 CHD-affected singletons, and 114 paired cardiovascular tissue/blood samples. The variant allele fraction (VAF) of heteroplasmic variants in mitochondrial RNA from 257 CHD cardiovascular tissue samples was also calculated. On average, mtDNA from blood had 0.14 rare variants and 52.9 mtDNA copies per nuclear genome per proband. No variation with parental age at proband birth or CHD-affected proband age was seen. mtDNAcns in valve/vessel tissue (320 ± 70) were lower than in atrial tissue (1,080 ± 320, p = 6.8E-21), which were lower than in ventricle tissue (1,340 ± 280, p = 1.4E-4). The frequency of rare variants in CHD-affected individual DNA was indistinguishable from the frequency in an unaffected cohort, and proband mtDNAcns did not vary from those of CHD cohort parents. In both the CHD and the comparison cohorts, mtDNAcns were significantly correlated between mother-child, father-child, and mother-father. mtDNAcns among people with European (mean = 52.0), African (53.0), and Asian haplogroups (53.5) were calculated and were significantly different for European and Asian haplogroups (p = 2.6E-3). Variant heteroplasmic fraction (HF) in blood correlated well with paired cardiovascular tissue HF (r = 0.975) and RNA VAF (r = 0.953), which suggests blood HF is a reasonable proxy for HF in heart tissue. We conclude that mtDNA mutations and mtDNAcns are unlikely to contribute significantly to CHD risk., Competing Interests: Declaration of interests The authors declare that they have no competing interests., (Copyright © 2022. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
12. Understanding resistant hypertension.
- Author
-
Bachinsky A, Jones EL, Thompson T, DePalma S, Nicholas J, and Schmidt E
- Subjects
- Antihypertensive Agents therapeutic use, Humans, Renin-Angiotensin System, Cardiovascular Diseases drug therapy, Hypertension drug therapy, Hypertension etiology
- Abstract
Abstract: Resistant hypertension affects about 17% of the US population. However, it is difficult to diagnose because of multiple factors that influence adequate treatment of BP, including patient lifestyle and comorbidities, improper therapeutic regimens, and secondary mechanisms. Possible causes of resistant hypertension include nonmodulator hypertension, which affects patients who have an inappropriate response to elevated sodium through the renin-angiotensin-aldosterone system. Early identification and frequent follow-up can help patients achieve BP goals more rapidly and may reduce morbidity and mortality associated with complications of hypertension, including cerebrovascular accident, cardiovascular disease, and kidney disease., (Copyright © 2021 American Academy of Physician Assistants.)
- Published
- 2021
- Full Text
- View/download PDF
13. Cardiomyocyte Proliferative Capacity Is Restricted in Mice With Lmna Mutation.
- Author
-
Onoue K, Wakimoto H, Jiang J, Parfenov M, DePalma S, Conner D, Gorham J, McKean D, Seidman JG, Seidman CE, and Saito Y
- Abstract
LMNA is one of the leading causative genes of genetically inherited dilated cardiomyopathy (DCM). Unlike most DCM-causative genes, which encode sarcomeric or sarcomere-related proteins, LMNA encodes nuclear envelope proteins, lamin A and C, and does not directly associate with contractile function. However, a mutation in this gene could lead to the development of DCM. The molecular mechanism of how LMNA mutation contributes to DCM development remains largely unclear and yet to be elucidated. The objective of this study was to clarify the mechanism of developing DCM caused by LMNA mutation. Methods and Results: We assessed cardiomyocyte phenotypes and characteristics focusing on cell cycle activity in mice with Lmna mutation. Both cell number and cell size were reduced, cardiomyocytes were immature, and cell cycle activity was retarded in Lmna mutant mice at both 5 weeks and 2 years of age. RNA-sequencing and pathway analysis revealed "proliferation of cells" had the most substantial impact on Lmna mutant mice. Cdkn1a , which encodes the cell cycle regulating protein p21, was strongly upregulated in Lmna mutants, and upregulation of p21 was confirmed by Western blot and immunostaining. DNA damage, which is known to upregulate Cdkn1a , was more abundantly detected in Lmna mutant mice. To assess the proliferative capacity of cardiomyocytes, the apex of the neonate mouse heart was resected, and recovery from the insult was observed. A restricted cardiomyocyte proliferating capacity after resecting the apex of the heart was observed in Lmna mutant mice. Conclusions: Our results strongly suggest that loss of lamin function contributes to impaired cell proliferation through cell cycle defects. The inadequate inborn or responsive cell proliferation capacity plays an essential role in developing DCM with LMNA mutation., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Onoue, Wakimoto, Jiang, Parfenov, DePalma, Conner, Gorham, McKean, Seidman, Seidman and Saito.)
- Published
- 2021
- Full Text
- View/download PDF
14. Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy.
- Author
-
Goli R, Li J, Brandimarto J, Levine LD, Riis V, McAfee Q, DePalma S, Haghighi A, Seidman JG, Seidman CE, Jacoby D, Macones G, Judge DP, Rana S, Margulies KB, Cappola TP, Alharethi R, Damp J, Hsich E, Elkayam U, Sheppard R, Alexis JD, Boehmer J, Kamiya C, Gustafsson F, Damm P, Ersbøll AS, Goland S, Hilfiker-Kleiner D, McNamara DM, and Arany Z
- Subjects
- Adult, Cardiomyopathies physiopathology, Female, Humans, Phenotype, Pregnancy, Retrospective Studies, Cardiomyopathies genetics, Peripartum Period genetics
- Abstract
Background: Peripartum cardiomyopathy (PPCM) occurs in ≈1:2000 deliveries in the United States and worldwide. The genetic underpinnings of PPCM remain poorly defined. Approximately 10% of women with PPCM harbor truncating variants in TTN (TTNtvs). Whether mutations in other genes can predispose to PPCM is not known. It is also not known if the presence of TTNtvs predicts clinical presentation or outcomes. Nor is it known if the prevalence of TTNtvs differs in women with PPCM and preeclampsia, the strongest risk factor for PPCM., Methods: Women with PPCM were retrospectively identified from several US and international academic centers, and clinical information and DNA samples were acquired. Next-generation sequencing was performed on 67 genes, including TTN , and evaluated for burden of truncating and missense variants. The impact of TTNtvs on the severity of clinical presentation, and on clinical outcomes, was evaluated., Results: Four hundred sixty-nine women met inclusion criteria. Of the women with PPCM, 10.4% bore TTNtvs (odds ratio=9.4 compared with 1.2% in the reference population; Bonferroni-corrected P [ P *]=1.2×10
-46 ). We additionally identified overrepresentation of truncating variants in FLNC (odds ratio=24.8, P *=7.0×10-8 ), DSP (odds ratio=14.9, P *=1.0×10-8 ), and BAG3 (odds ratio=53.1, P *=0.02), genes not previously associated with PPCM. This profile is highly similar to that found in nonischemic dilated cardiomyopathy. Women with TTNtvs had lower left ventricular ejection fraction on presentation than did women without TTNtvs (23.5% versus 29%, P =2.5×10-4 ), but did not differ significantly in timing of presentation after delivery, in prevalence of preeclampsia, or in rates of clinical recovery., Conclusions: This study provides the first extensive genetic and phenotypic landscape of PPCM and demonstrates that predisposition to heart failure is an important risk factor for PPCM. The work reveals a degree of genetic similarity between PPCM and dilated cardiomyopathy, suggesting that gene-specific therapeutic approaches being developed for dilated cardiomyopathy may also apply to PPCM, and that approaches to genetic testing in PPCM should mirror those taken in dilated cardiomyopathy. Last, the clarification of genotype/phenotype associations has important implications for genetic counseling.- Published
- 2021
- Full Text
- View/download PDF
15. EM-mosaic detects mosaic point mutations that contribute to congenital heart disease.
- Author
-
Hsieh A, Morton SU, Willcox JAL, Gorham JM, Tai AC, Qi H, DePalma S, McKean D, Griffin E, Manheimer KB, Bernstein D, Kim RW, Newburger JW, Porter GA Jr, Srivastava D, Tristani-Firouzi M, Brueckner M, Lifton RP, Goldmuntz E, Gelb BD, Chung WK, Seidman CE, Seidman JG, and Shen Y
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Humans, Infant, Mosaicism, Point Mutation, Young Adult, Heart Defects, Congenital genetics, Software
- Abstract
Background: The contribution of somatic mosaicism, or genetic mutations arising after oocyte fertilization, to congenital heart disease (CHD) is not well understood. Further, the relationship between mosaicism in blood and cardiovascular tissue has not been determined., Methods: We developed a new computational method, EM-mosaic (Expectation-Maximization-based detection of mosaicism), to analyze mosaicism in exome sequences derived primarily from blood DNA of 2530 CHD proband-parent trios. To optimize this method, we measured mosaic detection power as a function of sequencing depth. In parallel, we analyzed our cohort using MosaicHunter, a Bayesian genotyping algorithm-based mosaic detection tool, and compared the two methods. The accuracy of these mosaic variant detection algorithms was assessed using an independent resequencing method. We then applied both methods to detect mosaicism in cardiac tissue-derived exome sequences of 66 participants for which matched blood and heart tissue was available., Results: EM-mosaic detected 326 mosaic mutations in blood and/or cardiac tissue DNA. Of the 309 detected in blood DNA, 85/97 (88%) tested were independently confirmed, while 7/17 (41%) candidates of 17 detected in cardiac tissue were confirmed. MosaicHunter detected an additional 64 mosaics, of which 23/46 (50%) among 58 candidates from blood and 4/6 (67%) of 6 candidates from cardiac tissue confirmed. Twenty-five mosaic variants altered CHD-risk genes, affecting 1% of our cohort. Of these 25, 22/22 candidates tested were confirmed. Variants predicted as damaging had higher variant allele fraction than benign variants, suggesting a role in CHD. The estimated true frequency of mosaic variants above 10% mosaicism was 0.14/person in blood and 0.21/person in cardiac tissue. Analysis of 66 individuals with matched cardiac tissue available revealed both tissue-specific and shared mosaicism, with shared mosaics generally having higher allele fraction., Conclusions: We estimate that ~ 1% of CHD probands have a mosaic variant detectable in blood that could contribute to cardiac malformations, particularly those damaging variants with relatively higher allele fraction. Although blood is a readily available DNA source, cardiac tissues analyzed contributed ~ 5% of somatic mosaic variants identified, indicating the value of tissue mosaicism analyses.
- Published
- 2020
- Full Text
- View/download PDF
16. ViroFind: A novel target-enrichment deep-sequencing platform reveals a complex JC virus population in the brain of PML patients.
- Author
-
Chalkias S, Gorham JM, Mazaika E, Parfenov M, Dang X, DePalma S, McKean D, Seidman CE, Seidman JG, and Koralnik IJ
- Subjects
- Genes, Viral, Humans, JC Virus genetics, Brain virology, High-Throughput Nucleotide Sequencing methods, JC Virus isolation & purification, Leukoencephalopathy, Progressive Multifocal virology
- Abstract
Deep nucleotide sequencing enables the unbiased, broad-spectrum detection of viruses in clinical samples without requiring an a priori hypothesis for the source of infection. However, its use in clinical research applications is limited by low cost-effectiveness given that most of the sequencing information from clinical samples is related to the human genome, which renders the analysis of viral genomes challenging. To overcome this limitation we developed ViroFind, an in-solution target-enrichment platform for virus detection and discovery in clinical samples. ViroFind comprises 165,433 viral probes that cover the genomes of 535 selected DNA and RNA viruses that infect humans or could cause zoonosis. The ViroFind probes are used in a hybridization reaction to enrich viral sequences and therefore enhance the detection of viral genomes via deep sequencing. We used ViroFind to detect and analyze all viral populations in the brain of 5 patients with progressive multifocal leukoencephalopathy (PML) and of 18 control subjects with no known neurological disease. Compared to direct deep sequencing, by using ViroFind we enriched viral sequences present in the clinical samples up to 127-fold. We discovered highly complex polyoma virus JC populations in the PML brain samples with a remarkable degree of genetic divergence among the JC virus variants of each PML brain sample. Specifically for the viral capsid protein VP1 gene, we identified 24 single nucleotide substitutions, 12 of which were associated with amino acid changes. The most frequent (4 of 5 samples, 80%) amino acid change was D66H, which is associated with enhanced tissue tropism, and hence likely a viral fitness advantage, compared to other variants. Lastly, we also detected sparse JC virus sequences in 10 of 18 (55.5%) of control samples and sparse human herpes virus 6B (HHV6B) sequences in the brain of 11 of 18 (61.1%) control subjects. In sum, ViroFind enabled the in-depth analysis of all viral genomes in PML and control brain samples and allowed us to demonstrate a high degree of JC virus genetic divergence in vivo that has been previously underappreciated. ViroFind can be used to investigate the structure of the virome with unprecedented depth in health and disease state.
- Published
- 2018
- Full Text
- View/download PDF
17. De novo mutations in histone-modifying genes in congenital heart disease.
- Author
-
Zaidi S, Choi M, Wakimoto H, Ma L, Jiang J, Overton JD, Romano-Adesman A, Bjornson RD, Breitbart RE, Brown KK, Carriero NJ, Cheung YH, Deanfield J, DePalma S, Fakhro KA, Glessner J, Hakonarson H, Italia MJ, Kaltman JR, Kaski J, Kim R, Kline JK, Lee T, Leipzig J, Lopez A, Mane SM, Mitchell LE, Newburger JW, Parfenov M, Pe'er I, Porter G, Roberts AE, Sachidanandam R, Sanders SJ, Seiden HS, State MW, Subramanian S, Tikhonova IR, Wang W, Warburton D, White PS, Williams IA, Zhao H, Seidman JG, Brueckner M, Chung WK, Gelb BD, Goldmuntz E, Seidman CE, and Lifton RP
- Subjects
- Adult, Case-Control Studies, Child, Chromatin chemistry, Chromatin metabolism, DNA Mutational Analysis, Enhancer Elements, Genetic genetics, Exome genetics, Female, Genes, Developmental genetics, Heart Diseases metabolism, Histones chemistry, Humans, Lysine chemistry, Lysine metabolism, Male, Methylation, Mutation, Odds Ratio, Promoter Regions, Genetic genetics, Heart Diseases congenital, Heart Diseases genetics, Histones metabolism
- Abstract
Congenital heart disease (CHD) is the most frequent birth defect, affecting 0.8% of live births. Many cases occur sporadically and impair reproductive fitness, suggesting a role for de novo mutations. Here we compare the incidence of de novo mutations in 362 severe CHD cases and 264 controls by analysing exome sequencing of parent-offspring trios. CHD cases show a significant excess of protein-altering de novo mutations in genes expressed in the developing heart, with an odds ratio of 7.5 for damaging (premature termination, frameshift, splice site) mutations. Similar odds ratios are seen across the main classes of severe CHD. We find a marked excess of de novo mutations in genes involved in the production, removal or reading of histone 3 lysine 4 (H3K4) methylation, or ubiquitination of H2BK120, which is required for H3K4 methylation. There are also two de novo mutations in SMAD2, which regulates H3K27 methylation in the embryonic left-right organizer. The combination of both activating (H3K4 methylation) and inactivating (H3K27 methylation) chromatin marks characterizes 'poised' promoters and enhancers, which regulate expression of key developmental genes. These findings implicate de novo point mutations in several hundreds of genes that collectively contribute to approximately 10% of severe CHD.
- Published
- 2013
- Full Text
- View/download PDF
18. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
- Author
-
Baquero GA, Banchs JE, Depalma S, Young SK, Penny-Peterson ED, Samii SM, Wolbrette DL, Naccarelli GV, and Gonzalez MD
- Subjects
- Aged, Anti-Arrhythmia Agents administration & dosage, Anti-Arrhythmia Agents adverse effects, Cardiomyopathy, Dilated complications, Coronary Artery Disease complications, Death, Sudden, Cardiac prevention & control, Dose-Response Relationship, Drug, Electric Countershock, Female, Follow-Up Studies, Heart Failure complications, Humans, Male, Middle Aged, Phenethylamines administration & dosage, Phenethylamines adverse effects, Recurrence, Stroke Volume drug effects, Stroke Volume physiology, Sulfonamides administration & dosage, Sulfonamides adverse effects, Tachycardia, Ventricular physiopathology, Tachycardia, Ventricular therapy, Treatment Outcome, Ventricular Fibrillation physiopathology, Ventricular Fibrillation therapy, Ventricular Function, Left drug effects, Ventricular Function, Left physiology, Anti-Arrhythmia Agents therapeutic use, Defibrillators, Implantable, Phenethylamines therapeutic use, Sulfonamides therapeutic use, Tachycardia, Ventricular drug therapy, Ventricular Fibrillation drug therapy
- Abstract
Background: Patients with an implanted cardioverter defibrillator (ICD) and ventricular arrhythmias leading to ICD therapies have poor clinical outcomes and quality of life. Antiarrhythmic agents and catheter ablation are needed to control these arrhythmias. Dofetilide has only been approved for the treatment of atrial fibrillation. The role of dofetilide in the control of ventricular arrhythmias in patients with an ICD has not been established., Objective: Evaluate the safety and efficacy of dofetilide in a consecutive group of patients with an ICD and recurrent ventricular tachycardia (VT) and/ or ventricular fibrillation (VF) after other antiarrhythmic drugs have failed to suppress these arrhythmias., Methods: We studied 30 patients (age 59 ± 11; 5 women) with symptomatic VT or VF and ICDs for secondary prevention of sudden cardiac death. These patients had an average of 1.8 ± 4.5 episodes of VT/VF per month despite antiarrhymic therapy. Twenty-one patients (70%) had recurrent appropriate ICD therapies prior to initiation of dofetilide, and 9 (30%) VTs below the programmed detection rate of the ICD. Twenty-three patients (77%) had coronary artery disease. Mean ejection fraction was 30 ± 14% and 26/30 (87%) had congestive heart failure. All patients had previously failed 2 ± 1 antiarrhythmic drugs including amiodarone (n = 19) and sotalol (n = 10)., Results: During the first month of treatment, 25 patients (83%) had complete suppression of VT/VF and of the 21 patients with ICD therapies 16 (76%) had no therapies during the first month of treatment. During a follow-up period of 32 ± 32 months, dofetilide reduced the monthly episodes of VT/VF from 1.8 ± 4.5 to 1.0 ± 3.5 (P = 0.006). Monthly ICD therapies decreased from 0.9 ± 1.4 to 0.4 ± 1.7 (P = 0.037). In 9 patients that presented with slow VTs under the ICD detection zone, dofetilide reduced monthly VT/VF episodes from 0.7 ± 0.6 to 0.1 ± 0.1 (P = 0.01) and 6 (67%) had no further ICD therapies. Dofetilide was discontinued in 13 patients (43%) after 24 ± 30 months due to failure to control VT/VF (n = 7), placement of a left ventricular assist device (n = 3), catheter ablation (n = 1), heart transplantation (n = 1), and left ventricular restoration surgery (n = 1). There were 7 documented deaths (2 patients died suddenly; 3 patients of progressive heart failure; and 2 of non-cardiac causes)., Conclusions: In patients with an ICD and ventricular arrhythmias, dofetilide decreases the frequency of VT/VF and ICD therapies even when other antiarrhythmic agents, including amiodarone, have previously been ineffective. Recurrences still occur in some patients requiring catheter ablation, mechanical support, or heart transplantation., (© 2011 Wiley Periodicals, Inc.)
- Published
- 2012
- Full Text
- View/download PDF
19. Familial dilated cardiomyopathy caused by an alpha-tropomyosin mutation: the distinctive natural history of sarcomeric dilated cardiomyopathy.
- Author
-
Lakdawala NK, Dellefave L, Redwood CS, Sparks E, Cirino AL, Depalma S, Colan SD, Funke B, Zimmerman RS, Robinson P, Watkins H, Seidman CE, Seidman JG, McNally EM, and Ho CY
- Subjects
- Adolescent, Adult, Age Factors, Aged, Calcium metabolism, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Mutation, Myosins analysis, Phenotype, Tropomyosin genetics, Troponin metabolism, Ventricular Remodeling physiology, Cardiomyopathy, Dilated genetics, Sarcomeres genetics
- Abstract
Objectives: We sought to further define the role of sarcomere mutations in dilated cardiomyopathy (DCM) and associated clinical phenotypes., Background: Mutations in several contractile proteins contribute to DCM, but definitive evidence for the roles of most sarcomere genes remains limited by the lack of robust genetic support., Methods: Direct sequencing of 6 sarcomere genes was performed on 334 probands with DCM. A novel D230N missense mutation in the gene encoding alpha-tropomyosin (TPM1) was identified. Functional assessment was performed by the use of an in vitro reconstituted sarcomere complex to evaluate ATPase regulation and Ca(2+) affinity as correlates of contractility., Results: TPM1 D230N segregated with DCM in 2 large unrelated families. This mutation altered an evolutionarily conserved residue and was absent in >1,000 control chromosomes. In vitro studies demonstrated major inhibitory effects on sarcomere function with reduced Ca(2+) sensitivity, maximum activation, and Ca(2+) affinity compared with wild-type TPM1. Clinical manifestations ranged from decompensated heart failure or sudden death in those presenting early in life to asymptomatic left ventricular dysfunction in those diagnosed during adulthood. Notably, several affected infants had remarkable improvement., Conclusions: Genetic segregation in 2 unrelated families and functional analyses conclusively establish a pathogenic role for TPM1 mutations in DCM. In vitro results demonstrate contrasting effects of DCM and hypertrophic cardiomyopathy mutations in TPM1, suggesting that specific functional consequences shape cardiac remodeling. Along with previous reports, our data support a distinctive, age-dependent phenotype with sarcomere-associated DCM where presentation early in life is associated with severe, sometimes lethal, disease. These observations have implications for the management of familial DCM., (Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
20. Adsorption thermodynamics of p-arsanilic acid on iron (oxyhydr)oxides: in-situ ATR-FTIR studies.
- Author
-
Depalma S, Cowen S, Hoang T, and Al-Abadleh HA
- Subjects
- Adsorption, Ferric Compounds chemistry, Iron Compounds chemistry, Minerals, Spectroscopy, Fourier Transform Infrared, Thermodynamics, Arsanilic Acid chemistry
- Abstract
The organoarsenical p-arsanilic acid (p-AsA) is used in the U.S. poultry industry as a feed additive and its structure resembles one of the stable biodegradation products of Roxarsone (ROX) in anaerobic environments. With the implementation of recent EPA MCL of total arsenic in drinking water (10 ppb), thereareconcernsaboutthefate of organoarsenicals introduced to the environment through the application of arsenic-contaminated manure. We report herein, for the first time, the thermodynamics of p-AsA binding to Fe-(oxyhydr)oxides using ATR-FTIR. ATR-FTIR spectra were used to quantify surface coverage of p-AsA, p-AsA(ads), by analyzing the broadband assigned to v(As-O) at 837 cm(-1). Adsorption isotherms were measured in situ at 298 K and pH 7 in the concentration range 1 microM to 40 mM. Values of Keq were obtained from Langmuir model fits and they range from 1411 to 3228 M(-1). We also determined the maximum adsorption capacities of Fe-(oxyhydr)oxides to p-AsA, and they range from 1.9 x 10(13) to 2.6 x 10(13) molecules/cm2. Our results suggest that p-AsA is more mobile than methylated and inorganic forms of arsenic and that the transport of nanoparticles with p-AsA(ads) might play a role in its mobility in geochemical environments.
- Published
- 2008
- Full Text
- View/download PDF
21. Contribution of the superior colliculus and the mesencephalic reticular formation to gaze control.
- Author
-
Waitzman DM, Pathmanathan J, Presnell R, Ayers A, and DePalma S
- Subjects
- Animals, Electric Stimulation, Haplorhini, Head Movements physiology, Neurons, Eye Movements physiology, Reticular Formation physiology, Superior Colliculi physiology
- Abstract
Converging lines of evidence support a role for the intermediate and deep layers of the superior colliculus (SC) and the mesencephalic reticular formation (MRF) in the control of combined head and eye movements (i.e., gaze). Recent microstimulation, single-cell recording, and lesion experiments are reviewed in which monkeys are free to move their heads. Cells in the SC discharge in advance of combined head and eye movements and most likely provide a gaze error signal to downstream structures. In contrast, the neurons in the MRF are of at least two types. Eye cells have features that are similar to neurons in the rostral portion of the SC, but fire before the onset of horizontal eye movments. A second group of MRF neurons begin to fire after the onset of the gaze shift and are most closely associated with movements of the head. The peak discharge of these late-onset MRF neurons occurs near the peak head velocity. Stimulation in the rostral SC generates eye movements with fixed amplitude and direction. A similar response is noted after stimulation of the more dorsal portion of the caudal MRF. Stimulation in the caudal portion of the SC produces combined head and eye movements of fixed amplitude. Electrical activation of the more ventral portions of the caudal MRF generates goal-directed and centering eye movements. Temporary inactivation of the SC with the GABA agonist muscimol generated hypometria and curved trajectories of contralateral eye movements. Inactivation of the caudal MRF produced contralateral hypermetria and ipsilateral hypometria of saccades. Release of the monkey's head demonstrated a profound contralateral head tilt. Taken together, these data suggest that the gaze signal generated in the SC is filtered by neurons in the MRF to generate a feedback signal of eye motor error. The head signal found in the MRF could cancel a portion of the gaze signal coming from the SC in the form of head velocity feedback.
- Published
- 2002
- Full Text
- View/download PDF
22. Molecular epidemiology of hypertrophic cardiomyopathy.
- Author
-
Morita H, DePalma SR, Arad M, McDonough B, Barr S, Duffy C, Maron BJ, Seidman CE, and Seidman JG
- Subjects
- Actins genetics, Cardiomyopathy, Hypertrophic epidemiology, Cardiomyopathy, Hypertrophic pathology, Carrier Proteins genetics, DNA Mutational Analysis, Humans, Models, Molecular, Molecular Epidemiology, Mutation, Myosin Heavy Chains chemistry, Myosin Heavy Chains genetics, Myosin Light Chains genetics, Protein Conformation, Tropomyosin genetics, Troponin I genetics, Troponin T genetics, Cardiomyopathy, Hypertrophic genetics, Muscle Proteins genetics
- Published
- 2002
- Full Text
- View/download PDF
23. A nonsense mutation in MSX1 causes Witkop syndrome.
- Author
-
Jumlongras D, Bei M, Stimson JM, Wang WF, DePalma SR, Seidman CE, Felbor U, Maas R, Seidman JG, and Olsen BR
- Subjects
- Adult, Amino Acid Sequence, Animals, Anodontia embryology, Base Sequence, Chromosome Mapping, DNA Mutational Analysis, Female, Genes, Dominant genetics, Heterozygote, Homeodomain Proteins chemistry, Homeodomain Proteins metabolism, Humans, In Situ Hybridization, MSX1 Transcription Factor, Male, Mice, Mice, Knockout, Nails, Malformed embryology, Pedigree, Phenotype, Polymorphism, Genetic genetics, Protein Structure, Tertiary, RNA, Messenger analysis, RNA, Messenger genetics, Syndrome, Anodontia genetics, Codon, Nonsense genetics, Genetic Linkage genetics, Homeodomain Proteins genetics, Nails, Malformed genetics, Transcription Factors
- Abstract
Witkop syndrome, also known as tooth and nail syndrome (TNS), is a rare autosomal dominant disorder. Affected individuals have nail dysplasia and several congenitally missing teeth. To identify the gene responsible for TNS, we used candidate-gene linkage analysis in a three-generation family affected by the disorder. We found linkage between TNS and polymorphic markers surrounding the MSX1 locus. Direct sequencing and restriction-enzyme analysis revealed that a heterozygous stop mutation in the homeodomain of MSX1 cosegregated with the phenotype. In addition, histological analysis of Msx1-knockout mice, combined with a finding of Msx1 expression in mesenchyme of developing nail beds, revealed that not only was tooth development disrupted in these mice, but nail development was affected as well. Nail plates in Msx1-null mice were defective and were thinner than those of their wild-type littermates. The resemblance between the tooth and nail phenotype in the human family and that of Msx1-knockout mice strongly supports the conclusions that a nonsense mutation in MSX1 causes TNS and that Msx1 is critical for both tooth and nail development.
- Published
- 2001
- Full Text
- View/download PDF
24. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy.
- Author
-
Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, McDonough B, Smoot L, Mullen MP, Woolf PK, Wigle ED, Seidman JG, and Seidman CE
- Subjects
- Adolescent, Adult, Aged, Amino Acid Sequence, Cardiomyopathy, Dilated diagnostic imaging, Cardiomyopathy, Dilated pathology, Child, Child, Preschool, Chromosome Mapping, Chromosomes, Human, Pair 14, Female, Genes, Dominant, Humans, Infant, Male, Middle Aged, Molecular Sequence Data, Mutation, Missense, Myocardial Contraction genetics, Myocardial Contraction physiology, Myocardium pathology, Nonmuscle Myosin Type IIB, Pedigree, Sarcomeres physiology, Ultrasonography, Cardiomyopathy, Dilated genetics, Myosin Heavy Chains genetics, Sarcomeres genetics, Troponin T genetics
- Abstract
Background: The molecular basis of idiopathic dilated cardiomyopathy, a primary myocardial disorder that results in reduced contractile function, is largely unknown. Some cases of familial dilated cardiomyopathy are caused by mutations in cardiac cytoskeletal proteins; this finding implicates defects in contractile-force transmission as one mechanism underlying this disorder. To elucidate this important cause of heart failure, we investigated other genetic causes of dilated cardiomyopathy., Methods: Clinical evaluations were performed in 21 kindreds with familial dilated cardiomyopathy. A genome-wide linkage study prompted a search of the genes encoding beta-myosin heavy chain, troponin T, troponin I, and alpha-tropomyosin for disease-causing mutations., Results: A genetic locus for mutations associated with dilated cardiomyopathy was identified at chromosome 14q11.2-13 (maximal lod score, 5.11; theta=0), where the gene for cardiac beta-myosin heavy chain is encoded. Analyses of this and other genes for sarcomere proteins identified disease-causing dominant mutations in four kindreds. Cardiac beta-myosin heavy-chain missense mutations (Ser532Pro and Phe764Leu) and a deletion in cardiac troponin T (deltaLys210) caused early-onset ventricular dilatation (average age at diagnosis, 24 years) and diminished contractile function and frequently resulted in heart failure. Affected persons had neither antecedent cardiac hypertrophy (average maximal left-ventricular-wall thickness, 8.5 mm) nor histopathological findings characteristic of hypertrophy., Conclusion: Mutations in sarcomere protein genes account for approximately 10 percent of cases of familial dilated cardiomyopathy and are particularly prevalent in families with early-onset ventricular dilatation and dysfunction. Because distinct mutations in sarcomere proteins cause either dilated or hypertrophic cardiomyopathy, the effects of mutant sarcomere proteins on muscle mechanics must trigger two different series of events that remodel the heart.
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.